FEATURED EDITORIAL
Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.
- The Future Is Ancient: Evolution, Metabolics, And AI
- The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future
- Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
- Aligning Standards, Validation, And Governance For Digital Preclinical Research
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- Can Molecular Glue Degraders Make The Undruggable Druggable?
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
FEATURED APPLICATION CONTENT
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Lonza Expands HPAPI Capacity In Visp, Further Supporting Its Position In Payload-Linker Manufacturing
- Altasciences Supports Key Development Milestone For Steel Therapeutics' Lead Therapeutic Candidate, Fizurex
- Tsingke Biotech Hosts Shanghai Salon On Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
- Inductive Bio Joins Anthropic's Connector Ecosystem For Life Sciences, Surfacing State-Of-The-Art ADMET Prediction To Drug Discovery Scientists Through Claude
- Enhertu Approved In The EU As First Tumor Agnostic HER2 Directed Therapy And Antibody Drug Conjugate For Patients With Previously Treated HER2 Positive Metastatic Solid Tumors
- Key Milestone Achieved: NDA For Sumecigrel Capsule, An Antiplatelet Innovative Drug By Vcare Pharmatech, Officially Accepted
- Biolevate To Advance AI-Native Drug Discovery Workflows With NVIDIA BioNeMo Agent Toolkit
- VeriSIM Life Formalizes Research Collaboration With FDA/NCTR, Advancing The Next Generation Of Mechanistic AI For Drug Development
- HKeyBio Debuts HKEY-ExE™ 1.0 To Address Preclinical Bottlenecks In EoE And EgE Drug Developmen
- Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies
ARCHIVED NEWSLETTER
- 07.03.26 -- Drug Discovery Online Best Of June
- 06.30.26 -- A New De Novo Protein Design Platform For GPCR Drug Discovery
- 06.24.26 -- How Spray Drying Is Reshaping Modern Drug Development
- 06.16.26 -- Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort
- 06.09.26 -- Validation And Trust Are Biggests Barriers To Organ On Chip Adoption
